The Florida Silver Haired Legislature is advocating for federal Medicare reforms that would eliminate policies steering seniors toward opioid pain medications over non-addictive alternatives. The organization’s CEO-president Ernie Bach argues that current Medicare rules create unnecessary addiction risks for Florida seniors by making generic opioids cheaper and more accessible than FDA-approved non-opioid pain management options. Eight members of Florida’s congressional delegation have already signed on as cosponsors of the Alternatives to PAIN Act, demonstrating bipartisan support for the proposed changes.
“The Florida Silver Haired Legislature exists to make sure the voices of older Floridians are heard where decisions are made,” Bach said. “When we see a policy that is quietly putting seniors at unnecessary risk, speaking up is what we are here to do.” The legislation would address Medicare’s current tier system that routinely places generic opioids on lower, cheaper tiers while FDA-approved non-opioid alternatives sit on higher tiers with steeper copays.
During a recent House Energy and Commerce Committee hearing, Seminole County Sheriff Dennis Lemma emphasized the severity of the opioid crisis. “The best thing they can do is never start,” Lemma said regarding opioid use. The current Medicare system often requires patients to try opioids first through prior authorization rules and fail-first requirements before covering non-opioid alternatives, even when patients specifically want to avoid addictive medications.
The Alternatives to PAIN Act would implement two key changes to Medicare policy. The legislation would ensure Medicare beneficiaries never pay more for non-opioid pain medication than for opioids, and it would prohibit insurance plans from requiring opioid use as a precondition for covering non-opioid alternatives. More than 100 organizations nationwide have endorsed the bill, including physician associations, patient advocates, veterans’ groups and elder care organizations.
Meanwhile, other Medicare changes are taking effect that could impact Florida seniors’ healthcare costs. Ten prescription drugs with high costs for Medicare are now available at lower negotiated prices, including arthritis, blood clot, cancer and diabetes medications. The savings are expected to lower recipients’ out-of-pocket spending by an estimated $1.5 billion in 2026, with Medicare itself potentially saving about $6 billion based on 2023 usage patterns.
Additional Medicare coverage changes include new access to popular weight-loss drugs starting in July. Medicare Part D prescription plan enrollees who qualify will see GLP-1 medications like Mounjaro, Ozempic, Wegovy and Zepbound available at $50 per month through a six-month bridge program. Eligibility requires a body mass index higher than 35, or lower BMI levels with specific chronic conditions including prediabetes, cardiovascular disease, heart failure, uncontrolled high blood pressure or chronic kidney disease.
Bach emphasized that preventing unnecessary opioid exposure benefits patients, families and the Medicare program’s financial stability. “Seniors who are steered toward opioids unnecessarily face genuine risks of dependence, hospitalization and a difficult recovery cycle that no one should have to navigate,” he stated. The cost savings from avoiding addiction and its downstream consequences are described as predictable and significant.
The House Energy and Commerce Committee is expected to consider advancing the Alternatives to PAIN Act for a full House vote. A list of 15 additional high-cost drugs to be negotiated will be announced by Feb. 1, with those price reductions taking effect Jan. 1, 2027.